Global Sexually Transmitted Infections (STIs) Market, By Type (HIV/AIDS, Human Papilloma Virus (HPV), Gonorrhea, Syphilis, Others), Treatment (Antibiotics, Antiviral), Route of Administration (Oral, Parenteral, Others), Location of Testing (Laboratory Testing, Point-of-care (POC) Testing), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
According to World Health Organization (WHO), every day more than 1 million sexually transmitted infections (STIs) are acquired worldwide, with the majority of these infections being asymptomatic. Unprotected sexual contact is the most common way for sexually transmitted diseases (STIs) to spread. Some STIs can also be transferred by infected blood or blood products during pregnancy, childbirth, and nursing. STIs have a significant impact on one's health. They can cause catastrophic effects if left untreated, including neurological and cardiovascular disorders, infertility, ectopic pregnancy, stillbirths, and an increased chance of contracting the Human immunodeficiency virus (HIV). They're also linked to social stigma, domestic violence, and poor quality of life.
Data Bridge Market Research analyses that the sexually transmitted infections (STIs) market was valued at USD 49.51 billion in 2021 and is expected to reach USD 122.93 billion by 2029, registering a CAGR of 12.04% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (HIV/AIDS, Human Papilloma Virus (HPV), Gonorrhea, Syphilis, Others), Treatment (Antibiotics, Antiviral), Route of Administration (Oral, Parenteral, Others), Location of Testing (Laboratory Testing, Point-of-care (POC) Testing), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Cipla Inc. (U.S.), Hologic, Inc. (U.S.), BD (U.S.), Bristol-Myers Squibb Company (U.S.), Gilead Sciences, Inc. (U.S.), Bayer AG (Germany), Eli Lilly and Company (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Bausch Health Companies Inc. (Canada)
|
|
Market Opportunities
|
|
Market Definition
Sexually transmitted infections (STIs) are infections that are spread through sexual interaction. Bacteria, viruses, and parasites that cause sexually transmitted disorders can be passed from one person to another by blood, sperm, vaginal, and other physiological fluids. Nonsexual transmission of these infections is possible, for instance, from mothers to their infants during pregnancy or childbirth, or by blood transfusions or sharing needles. Three bacterial STIs (chlamydia, gonorrhoea, and syphilis) and one parasitic STI (trichomoniasis) are all treatable with single-dose antibiotic regimens.
Sexually Transmitted Infections (STIs) Market Dynamics
Drivers
- High prevalence rate of sexually transmitted infections (STIs)
The rise in prevalence rate of sexually transmitted infections (STIs) across the globe will act as a major driver that will result in the expansion of the growth rate of the market. As per the World Health Organization (WHO) estimation approximately 374 million new infections with one of four sexually transmitted infections (STIs) will occur in 2020: gonorrhoea (82 million), chlamydia (129 million), syphilis (7.1 million), and trichomoniasis (156 million). Vaginal discharge, genital ulcers, urethral discharge or burning in males and abdominal pain are all common STI symptoms.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of sexually transmitted infections (STIs) market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, surging number of government initiatives to spread awareness will result in the expansion of sexually transmitted infections (STIs) market. Along with this, changing lifestyle of people and favourable reimbursement policies will enhance the growth rate of the market. Also, implementation of national screening programs will propel the growth rate of market.
Opportunities
- Launch of new products
The rising number of launches of new products will create new market opportunities during the forecast period of 2022-2029. For instance, Hologic, Inc. announced in June 2019 that the US Food and Drug Administration had approved their Aptima Mycoplasma genitalium assay (FDA). Aptima is the first and only FDA-approved test for sexually transmitted infections, and it's becoming more popular (STI).
Moreover, the market's growth is fueled by investment for the development of advanced technologies and increase in the number of emerging markets. These factors will provide beneficial opportunities for the sexually transmitted infections (STIs) market growth. Additionally, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the sexually transmitted infections (STIs) market growth.
Restraints/Challenges
On the other hand, the high cost associated with the treatment will obstruct the growth rate of sexually transmitted infections (STIs) market during the forecast period of 2022-2029. The lack of healthcare infrastructure in developing economies and strict regulatory scenario will challenge the sexually transmitted infections (STIs) market. Additionally, lack of awareness among people and complications involved with the disease such as pregnancy complications, infertility, pelvic pain, eye inflammation, arthritis and others will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This sexually transmitted infections (STIs) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the sexually transmitted infections (STIs) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Sexually transmitted infections (STIs) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Recent Development
- In May 2022, Abbott announced United States Food and Drug Administration (FDA) clearance for its Alinity m STI Assay. After delays in care delivery during the pandemic contributed to a decline in routine STI screening and an increase in cases, the first-of-its-kind multiplex test will help address rising STI rates. Abbott's Alinity m system, the company's most advanced high-volume laboratory molecular equipment, is used for the test. Alinity m detects infectious infections using polymerase chain reaction (PCR) technology, which has a high sensitivity. This test can assist healthcare providers in saving time, increasing efficiency, and providing better patient care.
Global Sexually Transmitted Infections (STIs) Market Scope
The sexually transmitted infections (STIs) market is segmented on the basis of location of testing, type, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Location of Testing
- Laboratory Testing
- PCR
- Immunochromatographic assays
- Flow Cytometers
- Differential Light Scattering machines
- Enzyme Linked Immunosorbent Assay (ELISA)
- Others
- Point-of-care (POC) Testing
Type
- HIV/AIDS
- Human Papilloma Virus (HPV)
- Gonorrhea
- Syphilis
- Others
Treatment
- Antibiotics
- Antiviral
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Sexually Transmitted Infections (STIs) Market Regional Analysis/Insights
The sexually transmitted infections (STIs) market is analysed and market size insights and trends are provided by country, location of testing, type, treatment, route of administration, end-users and distribution channel as referenced above.
The countries covered in the sexually transmitted infections (STIs) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the sexually transmitted infections (STIs) market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing demand for specific treatment and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, presence of major key players and rise in adoption of newer technologies will further propel the market’s growth rate in this region.
Asia-Pacific is expected to be the fastest growing region during the forecast period of 2022-2029 due to growing cases of sexually transmitted infections (STIs) in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Sexually Transmitted Infections (STIs) Market Share Analysis
The sexually transmitted infections (STIs) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to sexually transmitted infections (STIs) market.
Some of the major players operating in the sexually transmitted infections (STIs) market are:
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Merck & Co., Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Cipla Inc. (U.S.)
- Hologic, Inc. (U.S.)
- BD (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Gilead Sciences, Inc. (U.S.)
- Bausch Health Companies Inc. (Canada)
SKU-